Back A A A Font Size Receive E-mail Alerts Press Releases

First Post-market Implantation of Castor® Successfully Completed


Suzhou, China – The first post-market implantation of Castor® Branched Aortic Stent-Graft System ("Castor®"), in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was recently successfully completed by Director Xiaoqiang Li of the Second Affiliated Hospital of Soochow University. The product gained the regulatory approval from China Food and Drug Administration in June 2017 to officially enter the China market.
The patient is a 72-year-old male who had been suffering from chest pain for two months prior to hospital admission. Preoperative CTA showed that the tear length was 29mm and LSA was involved by the false lumen. The distance between LSA and tear was 30mm according to evaluation of EndoSize software. The operation is quite challenging because: firstly, LSA is involved so that proximal landing zone needs to be extended to reduce the risk of retrograde dissection; secondly, due to the giant tear, the stent graft may slide into false lumen during or after deployment, causing main body stent graft migration; thirdly, the sharp angles of the arch is also a big challenge for proximal sealing effect.
With full understanding of such difficulties, Director Xiaoqiang Li chose to use MicroPort® Endovascular's Castor® for the treatment. He said: "Castor® extends the proximal landing zone to healthy area near the LSA, reducing the risk of retrograde dissection. The unibody design of Castor® can achieve double anchoring of LSA and thoracic aorta, preventing the stent graft from sliding into the false lumen, and reducing the risk of long-term migration."
The operation started with preoperative DSA performed through femoral artery. The angiography showed that the diameter of proximal was 29mm, so Director Xiaoqiang Li chose 34mm and tapered 6mm Castor®. Then, according to standard operating procedures, he established branch guide wire channel, and afterwards introduced and deployed the Castor® delivery system. When releasing the main body stent graft, the stent graft should be tightly enclosed the greater curve of the arch with fast deployment, so as to avoid sliding into false lumen. Intraoperative angiography showed precise positioning, no endoleak, and slightly slow LSA blood flow. In order to ensure the long-term patency, an 8*40 balloon was used for post-dilation, and a 10*40mm bare stent graft was implanted for prevention purpose. Postoperative angiography showed that the proximal triple stents provided excellent sealing effect with no type I endoleak, LSA remained patency, and the tear was completely isolated. The operation achieved successful result and Director Xiaoqiang Li spoke highly of Castor®'s clinical performance as well.
Castor® is the world's first stent graft specially designed for endovascular treatment of thoracic aorta and great vessels of the arch simultaneously. It is used for the treatment of thoracic aortic dissection. The device is delivered to the lesion by femoral artery, and after deployment, it will form a new blood flow channel to release the pressure to the vessel wall so as to prevent dissection rupture. Castor® extends the indication of the existing products and allows more patients with complex thoracic aortic aneurysm to receive interventional treatment instead of painful open surgery. Castor® adopts the unibody design, which is sewing the main body and branch stent together to make it possible to deploy and release at the same time. This design innovatively accomplishes deployment and positioning of the unibody branched stent graft, achieving low endoleak rate and better branch artery patency, while reducing the operative trauma and improving safety during the procedure. The launch of Castor® marks a significant step forward in using endovascular repair to treat aortic arch, making breakthroughs in a key area clinicians have spent many years to research and explore.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Orthopedics Hosts SuperPath™ Hip Arthroplasty and Fast Recovery Seminar
[Next]:MicroPort® Hosts Supply Chain Innovation Summit